HLA-A2-restricted melanoma-associated peptide-MHC class I complex (HLA-A2/pMHC)

HLA-A2-restricted melanoma-associated peptide-MHC class I complexes are specialized molecular assemblies found on the surface of melanoma cells, consisting of a tumor-specific peptide bound to the HLA-A*02:01 molecule (Nathan et al., 2021, NEJM). These complexes play a pivotal role in the immune system by presenting intracellular tumor antigens, such as gp100, MART-1, or MAGE-A4, to CD8+ cytotoxic T lymphocytes (Boon et al., 2006, Annu Rev Immunol). Recognition of these complexes by T-cell receptors (TCRs) triggers an immune response aimed at destroying the malignant cell (Janeway et al., 2001, Immunobiology). In modern oncology, these complexes serve as high-precision therapeutic targets for TCR-engineered T-cell therapies and bispecific T-cell engagers like Tebentafusp (Middleton et al., 2020, Clin Cancer Res). The efficacy of such treatments is strictly dependent on the patient's HLA-A*02:01 genotype and the robust expression of the target antigen within the tumor (D'Angelo et al., 2024, Lancet). However, challenges such as HLA downregulation and potential cross-reactivity with similar peptides in healthy tissues remain significant hurdles in clinical application (Barker et al., 2021, Front Immunol).

Other names

HLA-A*02:01-peptide complexMelanoma-associated pMHCMHC-peptide complexHLA-A2/Melanoma antigen complex

T-cell redirection and activation via T-cell receptor (TCR) recognition of specific peptide-MHC complexes, leading to targeted lysis of tumor cells (Nathan et al., 2021, NEJM).